Lupin Ltd has signed a non-exclusive patent licence agreement with Takeda Pharmaceutical to commercialise Vonoprazan tablets in India. The drug, approved for various gastrointestinal conditions, will be marketed as Lupivon in 10 mg and 20 mg strengths. This agreement aims to enhance Lupin's gastroenterology portfolio and address unmet patient needs. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
